Could This Tiny Biotech Be the Key to Stopping a Measles Comeback?

Could This Tiny Biotech Be the Key to Stopping a Measles Comeback?

The Measles Problem Is Back — And Getting Worse

Measles, once nearly eradicated in the U.S., is making an alarming return. Thanks to declining vaccination rates, experts warn the virus could become “endemic” again — meaning it continuously circulates through communities, much like the flu.

A recent Stanford study raised the alarm: if current trends continue, measles could regain a permanent foothold in the U.S. within years. As of April 2025, there have been 884 confirmed cases across 30 states — a sharp increase in both frequency and geographic spread.

Why the resurgence? Vaccine hesitancy, misinformation, and gaps in public trust have all played a role. Unfortunately, once measles gains momentum, it's hard to stop — it’s one of the most contagious viruses known.

That’s where NanoViricides Inc. (NYSE American: NNVC) comes in with a potential game-changer.

NanoViricides: A New Approach to Fighting Old Viruses

NanoViricides is a small but innovative biotech company developing broad-spectrum antiviral drugs using nanomedicine. Their flagship drug candidate, NV-387, is designed to work against multiple viruses — including RSV, COVID-19, flu, and now, measles.

In simple terms: NV-387 acts like a decoy. It mimics the sites on human cells that viruses latch onto. When a virus tries to attach, NV-387 captures and neutralizes it, stopping infection in its tracks.

This isn’t just theory. NV-387 has already shown it can cure lethal RSV infections in animal models. Since measles and RSV use similar mechanisms to infect cells, scientists believe NV-387 has strong potential to combat measles as well.

Why Measles Needs an Antiviral (Not Just a Vaccine)

While the measles vaccine is highly effective, vaccination rates are slipping. And even vaccinated individuals aren’t 100% immune forever. As a result, experts warn that the “vaccine-only” strategy might not be enough in the long run.

Unlike diseases like HIV or hepatitis C, measles currently has no approved antiviral treatment. If someone catches it, doctors can only offer supportive care.

NanoViricides is aiming to fill this gap.

Dr. Anil Diwan, President of NanoViricides, put it bluntly:

“A drug for measles is a completely missing link in outbreak response. Viral spread cannot be contained without effective treatment to minimize illness and stop transmission.”

Having an antiviral like NV-387 could do two critical things:

• Help infected patients recover faster
• Reduce how much they spread the virus to others

This approach would be a powerful complement to vaccines — giving health officials an extra tool to control outbreaks, especially in under-vaccinated areas.

The Science in Plain English: How NV-387 Works

NV-387 isn’t just a drug for measles. It’s designed as a broad-spectrum antiviral, effective against multiple viruses that use common entry pathways to infect human cells.

Here’s what makes it different:

• Acts as a virus decoy
• Binds and neutralizes viruses before they infect cells
• Harder for viruses to mutate around this mechanism

In early tests, NV-387 has been shown to outperform existing antivirals for viruses like influenza and COVID-19 in animal models. It has already passed Phase I human trials with no safety issues reported.

Now, NanoViricides is conducting studies to test NV-387 directly against the measles virus in specially designed lab models. Positive results could fast-track its relevance as a go-to treatment for future outbreaks.

Why Analysts Think NNVC Could Reach $6

At the time of writing, NanoViricides trades near $1–$1.50 per share. But some analysts have issued price targets as high as $6.50 — implying a potential 300%–400% upside.

This optimism comes from:

• The growing global need for broad-spectrum antivirals
• NV-387’s early success against multiple viruses
• The potential for partnerships or licensing deals
• The urgent public health gap for measles treatments

Unlike single-disease biotech plays, NanoViricides has multiple “shots on goal” with NV-387 targeting RSV, flu, COVID variants, Mpox, and measles. Each indication adds to the company’s potential market value.

High Risk, High Reward — But Timely

Of course, investing in early-stage biotech comes with risks. NV-387 still needs to succeed in further trials and eventually gain regulatory approval. But the addressable market is huge, and the need for new antiviral solutions is real.

For investors looking at asymmetric opportunities in healthcare, NanoViricides offers a compelling narrative:

• A rising public health problem (measles resurgence)
• A novel, broad-spectrum treatment strategy
• Analyst-backed price targets with significant upside potential

If NV-387 proves effective against measles and other viruses, NanoViricides could transform from an under-the-radar biotech into a key player in global infectious disease defense.

Disclaimer: The information presented in this newsletter regarding NanoViricides Inc. (NASDAQ: NNVC) is intended strictly for informational and educational purposes. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any securities. Readers are strongly encouraged to conduct their own due diligence or consult with a licensed financial advisor before making any investment decisions. If you wish to learn more about NanoViricides Inc., please visit their official investor relations page at www.nanoviricides.com. Cashu Technologies Pty Ltd. has been engaged by a third party to create and distribute this promotional content. While reasonable efforts have been made to ensure the accuracy and reliability of the information presented, no representation or warranty is made as to its completeness or timeliness. Any investment decision made based on the content of this newsletter is done at your own risk. Cashu Technologies Pty Ltd. expressly disclaims any and all liability for any loss or damage arising from reliance on the information provided herein.